OBJECTIVE: To assess for the increased risk of attention-deficit hyperactivity disorder (ADHD) in young children with prenatal methamphetamine exposure from the multicenter, longitudinal Infant Development, Environment, and Lifestyle (IDEAL) study. METHODS: The IDEAL study enrolled 412 mother-infant pairs at 4 sites (Tulsa, OK; Des Moines, IA; Los Angeles, CA; and Honolulu, HI). Methamphetamine-exposed subjects (n = 204) were identified by self-report and/or gas chromatography/mass spectrometry confirmation of amphetamine and metabolites in infant meconium. Matched subjects (n = 208) denied methamphetamine use and had a negative meconium screen. This analysis included a subsample of 301 subjects who were administered the Conners' Kiddie Continuous Performance Test (K-CPT) at 5.5 years of age (153 exposed and 148 comparison). Hierarchical linear models adjusted for covariates tested exposure effects on K-CPT measures. Using the same covariates, logistic regression was used to determine the effect of exposure on the incidence of a positive ADHD confidence index score, defined as greater than 50%. RESULTS: There were no differences between the groups in omission or commission errors or reaction time for correct trials. However, methamphetamine exposure was associated with subtle differences in other outcomes predictive of ADHD, including increased slope of reaction time across blocks (p < .001), increased variability in reaction time with longer interstimulus intervals (p < .01), and increased likelihood of greater than 50% on the ADHD confidence index (odds ratio, 3.1; 95% confidence interval, 1.2-7.8; p = .02). CONCLUSION: Prenatal methamphetamine exposure was associated with subtle differences in K-CPT scores at 5.5 years of age. Even at this relatively young age, these children exhibit indicators of risk for ADHD and warrant monitoring.
OBJECTIVE: To assess for the increased risk of attention-deficit hyperactivity disorder (ADHD) in young children with prenatal methamphetamine exposure from the multicenter, longitudinal Infant Development, Environment, and Lifestyle (IDEAL) study. METHODS: The IDEAL study enrolled 412 mother-infant pairs at 4 sites (Tulsa, OK; Des Moines, IA; Los Angeles, CA; and Honolulu, HI). Methamphetamine-exposed subjects (n = 204) were identified by self-report and/or gas chromatography/mass spectrometry confirmation of amphetamine and metabolites in infant meconium. Matched subjects (n = 208) denied methamphetamine use and had a negative meconium screen. This analysis included a subsample of 301 subjects who were administered the Conners' Kiddie Continuous Performance Test (K-CPT) at 5.5 years of age (153 exposed and 148 comparison). Hierarchical linear models adjusted for covariates tested exposure effects on K-CPT measures. Using the same covariates, logistic regression was used to determine the effect of exposure on the incidence of a positive ADHD confidence index score, defined as greater than 50%. RESULTS: There were no differences between the groups in omission or commission errors or reaction time for correct trials. However, methamphetamine exposure was associated with subtle differences in other outcomes predictive of ADHD, including increased slope of reaction time across blocks (p < .001), increased variability in reaction time with longer interstimulus intervals (p < .01), and increased likelihood of greater than 50% on the ADHD confidence index (odds ratio, 3.1; 95% confidence interval, 1.2-7.8; p = .02). CONCLUSION: Prenatal methamphetamine exposure was associated with subtle differences in K-CPT scores at 5.5 years of age. Even at this relatively young age, these children exhibit indicators of risk for ADHD and warrant monitoring.
Authors: Linda Chang; Lynne M Smith; Christine LoPresti; M Lynn Yonekura; Jennifer Kuo; Irwin Walot; Thomas Ernst Journal: Psychiatry Res Date: 2004-12-15 Impact factor: 3.222
Authors: Linda L LaGasse; Chris Derauf; Lynne M Smith; Elana Newman; Rizwan Shah; Charles Neal; Amelia Arria; Marilyn A Huestis; Sheri DellaGrotta; Hai Lin; Lynne M Dansereau; Barry M Lester Journal: Pediatrics Date: 2012-03-19 Impact factor: 7.124
Authors: Julia S Noland; Lynn T Singer; Elizabeth J Short; Sonia Minnes; Robert E Arendt; H Lester Kirchner; Cynthia Bearer Journal: Neurotoxicol Teratol Date: 2005-03-29 Impact factor: 3.763
Authors: Barry M Lester; Edward Z Tronick; Linda LaGasse; Ronald Seifer; Charles R Bauer; Seetha Shankaran; Henrietta S Bada; Linda L Wright; Vincent L Smeriglio; Jing Lu; Loretta P Finnegan; Penelope L Maza Journal: Pediatrics Date: 2002-12 Impact factor: 7.124
Authors: Sabrina D Diaz; Lynne M Smith; Linda L LaGasse; Chris Derauf; Elana Newman; Rizwan Shah; Amelia Arria; Marilyn A Huestis; Sheri Della Grotta; Lynne M Dansereau; Charles Neal; Barry M Lester Journal: J Pediatr Date: 2014-03-12 Impact factor: 4.406
Authors: Nwando Eze; Lynne M Smith; Linda L LaGasse; Chris Derauf; Elana Newman; Amelia Arria; Marilyn A Huestis; Sheri A Della Grotta; Lynne M Dansereau; Charles Neal; Barry M Lester Journal: J Pediatr Date: 2016-01-11 Impact factor: 4.406
Authors: Fleur L Warton; Paul A Taylor; Christopher M R Warton; Christopher D Molteno; Pia Wintermark; Nadine M Lindinger; Lilla Zöllei; Andre van der Kouwe; Joseph L Jacobson; Sandra W Jacobson; Ernesta M Meintjes Journal: Metab Brain Dis Date: 2017-10-23 Impact factor: 3.584
Authors: Lynne M Smith; Sabrina Diaz; Linda L LaGasse; Trecia Wouldes; Chris Derauf; Elana Newman; Amelia Arria; Marilyn A Huestis; William Haning; Arthur Strauss; Sheri Della Grotta; Lynne M Dansereau; Charles Neal; Barry M Lester Journal: Neurotoxicol Teratol Date: 2015-07-23 Impact factor: 3.763
Authors: Sarah K Himes; Linda L LaGasse; Chris Derauf; Elana Newman; Lynne M Smith; Amelia M Arria; Sheri A Della Grotta; Lynne M Dansereau; Beau Abar; Charles R Neal; Barry M Lester; Marilyn A Huestis Journal: Ther Drug Monit Date: 2014-08 Impact factor: 3.681